Case report: Successful treatment of a patient with relapsed/refractory primary central nervous system lymphoma with thiotepa-based induction, autologous stem cell transplantation and maintenance
Despite significant improvements in prognosis, a subset of patients with primary central nervous system lymphoma (PCNSL) remains at high risk for relapse. The treatment of relapsed and refractory (R/R) PCNSL remains a major clinical challenge. Herein, we present a 24-year-old patient with PCNSL who relapsed 4 years after initial diagnosis and subsequently became refractory to high-dose methotrexate (HD-MTX), temozolomide, whole brain radiation therapy (WBRT), ibrutinib, and lenalidomide. She received thiotepa with anti-programmed cell death protein 1 (PD-1) antibody and achieved partial remission and then underwent autolog...
Source: Frontiers in Oncology - January 29, 2024 Category: Cancer & Oncology Source Type: research
Iron-based biomarkers for personalizing pharmacological ascorbate therapy in glioblastoma: insights from a phase 2 clinical trial
ConclusionsThis study analyzes iron-related biomarkers in the context of P-AscH− therapy for glioblastoma. Integrating molecular, systemic, and imaging-based markers offers a multifaceted approach to tailoring treatment strategies, thereby contributing to improved patient outcomes and advancing the field of glioblastoma therapy. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 29, 2024 Category: Cancer & Oncology Source Type: research
Expression of molecular markers and synergistic anticancer effects of chemotherapy with antimicrobial peptides on glioblastoma cells
ConclusionsThe combination of antimicrobial peptides and chemical drugs enhances the cytotoxicity of chemotherapy and exerts synergistic antitumor effects in primary GBM cells. Moreover, in vivo study provided the first evidence that LL-37 could effectively inhibit brain tumor growth in rat C6 intracerebral GBM model. These results suggested a significant strategy for proposing a promising therapy for the treatment of GBM.Graphical Abstract (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - January 27, 2024 Category: Cancer & Oncology Source Type: research
Retraction: Inhibition of microRNA-299-5p sensitizes glioblastoma cells to temozolomide via the MAPK/ERK signaling pathway
Biosci Rep. 2024 Jan 31;44(1):BSR-2018-1051_RET. doi: 10.1042/BSR-2018-1051_RET.NO ABSTRACTPMID:38268333 | PMC:PMC10830440 | DOI:10.1042/BSR-2018-1051_RET (Source: Bioscience Reports)
Source: Bioscience Reports - January 25, 2024 Category: Biomedical Science Source Type: research
Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma
There are limited and no standard therapies for recurrent glioblastoma. We herein report the antitumour activity and safety of sintilimab, bevacizumab and temozolomide (TMZ) in recurrent glioblastoma. (Source: BMC Cancer)
Source: BMC Cancer - January 25, 2024 Category: Cancer & Oncology Authors: Yinghao Lu, Limin Liao, Kunpeng Du, Jianhua Mo, Xia Zou, Junxian Liang, Jiahui Chen, Wenwen Tang, Liwei Su, Jieping Wu, Junde Zhang and Yujing Tan Tags: Research Source Type: research
Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide
ConclusionTargeting AG4 with EGFR BATs at the maximum feasible dose of 80 × 109, with or without TMZ was safe and induced significant anti-tumor-specific immune responses. These results support further clinical trials to examine the efficacy of this adoptive cell therapy in patients with MGMT-unmethylated GBM.ClinicalTrials.gov Identifier: NCT03344250 (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 23, 2024 Category: Cancer & Oncology Source Type: research
From serendipity to intention: development of brain penetrant PARP1 selective inhibitors
Clin Cancer Res. 2024 Jan 22. doi: 10.1158/1078-0432.CCR-23-3571. Online ahead of print.ABSTRACTPrimary and secondary brain tumors cause significant mortality and constitute an important unmet need. The development of AZD9574, a brain-penetrant, PARP1 selective inhibitor, with favorable pharmacologic properties and intriguing preclinical activity, has led to an ongoing clinical trial evaluating it alone and in combination with temozolomide or antibody drug conjugates.PMID:38251977 | DOI:10.1158/1078-0432.CCR-23-3571 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - January 22, 2024 Category: Cancer & Oncology Authors: Filipa Lynce Nancy U Lin Source Type: research
Microneedle Patch Delivery of PLCG1-siRNA Efficient Enhanced Temozolomide Therapy for Glioblastoma
Biomacromolecules. 2024 Feb 12;25(2):655-665. doi: 10.1021/acs.biomac.3c00846. Epub 2024 Jan 19.ABSTRACTThe blood-brain barrier (BBB) and drug resistance present challenges for chemotherapy of glioblastoma (GBM). A microneedle (MN) patch with excellent biocompatibility and biodegradability was designed to bypass the BBB and release temozolomide (TMZ) and PLCG1-siRNA directly into the tumor site for synergistic treatment of GBM. The codelivery of TMZ and PLCG1-siRNA enhanced DNA damage and apoptosis. The potential mechanism behind this enhancement is to knockdown of PLCG1 expression, which positively regulates the expressio...
Source: Biomacromolecules - January 19, 2024 Category: Biochemistry Authors: Zhipeng Yang Yanjie Liu Haoyuan Li Qisheng Tang Biao Yang Zhifeng Shi Ying Mao Source Type: research
Ultrastructural and immunohistochemical insights on the anti-glioma effects of a dual-drug cocktail in an < em > in vivo < /em > experimental model
J Chemother. 2024 Jan 19:1-14. doi: 10.1080/1120009X.2024.2302741. Online ahead of print.ABSTRACTGlioma coined as 'butterfly tumor' exhibits intense heterogeneity at the molecular and cellular levels. Although, Temozolomide exerted a long-ranging and prevailing therapeutic effect against glioma, albeit it has provided modest survival outcome. Fucoidan, (marine brown algal derivative) has demonstrated potent anti-tumor effects including glioma. Nevertheless, there is paucity of studies conducted on Fucoidan to enhance the anti-glioma efficacy of Temozolomide. The present study aimed to explore the plausible synergistic anti...
Source: Journal of Chemotherapy - January 19, 2024 Category: Cancer & Oncology Authors: Indrani Biswas Daisy Precilla S Shreyas S Kuduvalli Bhavani K Sivachandran R Anitha T S Source Type: research
GSE211272 ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines
Contributors : Mathew Lozinski ; Paul A Tooney ; Nikola A Bowden ; Moira C Graves ; Michael Fay ; Bryan W Day ; Brett W StringerSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensGlioblastoma is an aggressive and highly invasive disease that often resists treatment. Tumour cells can restrict the DNA-damaging effects of temozolomide (TMZ) and radiation therapy (RT) using the DNA damage response (DDR) mechanism which activates cell cycle arrest and DNA repair pathways. Ataxia-telangiectasia and Rad3-Related protein (ATR) plays a pivotal role in the recognition of DNA damage induced by ch...
Source: GEO: Gene Expression Omnibus - January 18, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Small Warriors of Nature: Novel Red Emissive Chlorophyllin Carbon Dots Harnessing Fenton ‐Fueled Ferroptosis for In Vitro and In Vivo Cancer Treatment
In a groundbreaking development, copper chlorophyllin-based carbon dots (Chl-D CDs) are synthesized, displaying unique red emissive traits, and enhancing photodynamic therapy (PDT) by harnessing Fenton-like reaction. Chl-D CDs' ability to enhance PDT through ferroptotic and apoptotic pathways offers a secure and efficient approach to combined cancer therapy, making them an intriguing topic for exploration. AbstractThe appeal of carbon dots (CDs) has grown recently, due to their established biocompatibility, adjustable photoluminescence properties, and excellent water solubility. For the first time in the literature, copper...
Source: Small - January 17, 2024 Category: Nanotechnology Authors: Emel Kirbas Cilingir,
Omur Besbinar,
Linda Giro,
Mattia Bartoli,
Jose L. Hueso,
Keenan J. Mintz,
Yagmur Aydogan,
Jordan M. Garber,
Mine Turktas,
Okan Ekim,
Ahmet Ceylan,
Mehmet Altay Unal,
Mine Ensoy,
Fikret Ar ı,
Ozge Ozgenç Çinar,
Berf Tags: Research Article Source Type: research
ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines
Oncotarget. 2024 Jan 16;15:1-18. doi: 10.18632/oncotarget.28551.ABSTRACTGlioblastoma cells can restrict the DNA-damaging effects of temozolomide (TMZ) and radiation therapy (RT) using the DNA damage response (DDR) mechanism which activates cell cycle arrest and DNA repair pathways. Ataxia-telangiectasia and Rad3-Related protein (ATR) plays a pivotal role in the recognition of DNA damage induced by chemotherapy and radiation causing downstream DDR activation. Here, we investigated the activity of gartisertib, a potent ATR inhibitor, alone and in combination with TMZ and/or RT in 12 patient-derived glioblastoma cell lines. W...
Source: Oncotarget - January 16, 2024 Category: Cancer & Oncology Authors: Mathew Lozinski Nikola A Bowden Moira C Graves Michael Fay Bryan W Day Brett W Stringer Paul A Tooney Source Type: research
Molecular prognostic of nine parthanatos death ‐related genes in glioma, particularly in COL8A1 identification
A total of 11 parthanatos genes from ParthanatosCluster database were used to obtain the 9 ParthanatosScore prognostic genes combination. ParthanatosScore was verified by 656 patients and 979 patients in TCGA and CGGA-LGG/GBM datasets. COL8A1 was screened from nine ParthanatosScore prognostic genes through the glioma cell lines and survival analysis. Silencing COL8A1 inhibited the malignant characterization. Temozolomide and AZD3759 inhibited COL8A1 expression and cell viability and promoted apoptosis and parthanatos gene expression, which is a target to improve glioma. CGGA, Chinese Glioma Genome Atlas; GBM, Glioblastoma;...
Source: Journal of Neurochemistry - January 16, 2024 Category: Neuroscience Authors: Shuangshi Fan,
Hao Li,
Kun Liu Tags: ORIGINAL ARTICLE Source Type: research
dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma
ConclusiondCas9/CRISPR is a viable method of epigenetic editing, using the DNMT3A catalytic domain. This study provides initial proof-of-principle for CRISPR technology applications in malignant glioma, laying groundwork for subsequent translational studies, with implications for future epigenetic editing-based clinical applications. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - January 15, 2024 Category: Cancer & Oncology Source Type: research
NRP1 Induces Enhanced Stemness and Chemoresistance in Glioma Cells via YAP
In this study, we observed the effects of NRP1 on the stemness and chemoresistance of glioma cells and the mediating role of Yes-associated protein (YAP). We constructed NRP1 overexpressing LN-229 glioma cells. Cells were treated with recombinant NRP1 protein (rNRP1) and the YAP inhibitor Super-TDU when necessary. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to detect the sensitivity of cells to temozolomide (TMZ). Sphere and clone formation assays were performed to detect the sphere- and clone-forming abilities of cells. Western blotting was performed to detect cellular CD133, CD44, p-...
Source: Biological and Pharmaceutical Bulletin - January 14, 2024 Category: Drugs & Pharmacology Authors: Liang Jin Ai Jin Ling Wang Xiaoru Qi Yan Jin Chunhe Zhang Mengya Niu Source Type: research
